Dual Ca2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes.
The oxidative modification of LDL seems a key event in atherogenesis and may participate in inflammatory tissue injury. Our previous studies suggested that the process of LDL oxidation by activated human monocytes/macrophages required O2- and activity of intracellular lipoxygenase. Herein, we studied the mechanisms involved in this oxidative modification of LDL. In this study, we used the human monocytoid cell line U937 to examine the role of Ca2+ in U937 cell-mediated lipid peroxidation of LDL. U937 cells were activated by opsonized zymosan. Removal of Ca2+ from cell culture medium by EGTA inhibited U937 cell-mediated peroxidation of LDL lipids. Therefore, Ca2+ influx and mobilization were examined for their influence on U937 cell-mediated LDL lipid peroxidation. Ca2+ channel blockers nifedipine and verapamil blocked both Ca2+ influx and LDL lipid peroxidation by activated U937 cells. The inhibitory effects of nifedipine and verapamil were dose dependent. TMB-8 and ryanodine, agents known to prevent Ca2+ release from intracellular stores, also caused a dose-dependent inhibition of LDL lipid peroxidation by activated U937 cells while exhibiting no effect on Ca2+ influx. Thus, both Ca2+ influx through functional calcium channels and Ca2+ mobilization from intracellular stores participate in the oxidative modification of LDL by activated U937 cells. 45Ca2+ uptake experiments revealed profound Ca2+ influx during the early stages of U937 cell activation, however, the Ca2+ ionophore 4-bromo A23187 was unable to induce activation of U937 cells and peroxidation of LDL lipids. Release of intracellular Ca2+ by thapsigargin only caused a suboptimal peroxidation of LDL lipids. Our results indicate that although increases in intracellular Ca2+ levels provided by both influx and intracellular Ca2+ mobilization are required, other intracellular signals may be involved for optimal peroxidation of LDL lipids by activated human monocytes.
Li
Q
Q
Research Institute, Cleveland Clinic Foundation, Ohio 44195.
Tallant
A
A
Cathcart
M K
MK
D000975:Antioxidants / Q000494:pharmacology; D002118:Calcium / Q000502:physiology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D005110:Extracellular Space / Q000737:chemistry / Q000378:metabolism; D005707:Gallic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007424:Intracellular Fluid / Q000737:chemistry; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008262:Macrophage Activation / Q000502:physiology*; D008315:Malondialdehyde / Q000032:analysis; D009000:Monocytes / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology; D012433:Ryanodine / Q000494:pharmacology; D013858:Thiobarbiturates; D014407:Tumor Cells, Cultured
D000975:Antioxidants; D002121:Calcium Channel Blockers; D008077:Lipoproteins, LDL; D013858:Thiobarbiturates; D012433:Ryanodine; D008315:Malondialdehyde; C006014:8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate; D005707:Gallic Acid; D009543:Nifedipine; C029684:thiobarbituric acid; D002118:Calcium